Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein)
Maritati F., Fenoglio R., Pillebout E., Emmi G., Urban M. L., Rocco R., Nicastro M., Incerti M., Goldoni M., Trivioli G., Silvestri E., Mohammad A. J., Jayne D., Eriksson P., Segelmark M., Novikov P. I., Harris H., Roccatello D., Vaglio A.
Arthritis and Rheumatology
Vol.70, Issue1, P. 109-114
Опубликовано: 2018
Тип ресурса: Статья
Аннотация:
Objective: Adult-onset IgA vasculitis (Henoch-Schönlein) (IgAV) is a rare systemic vasculitis characterized by IgA1-dominant deposits. The treatment of adult-onset IgAV is controversial and is based on the combination of glucocorticoids and immunosuppressive agents, but many patients have refractory or relapsing disease despite treatment. Rituximab (RTX) is a B cell–depleting antibody of proven efficacy in antineutrophil cytoplasmic antibody–associated vasculitis. We undertook this study to test the efficacy and safety of RTX in a multicenter cohort of patients with adult-onset IgAV. Methods: In this multicenter observational study, we included patients with adult-onset IgAV who had received RTX either for refractory/relapsing disease or because they had contraindications to conventional glucocorticoid/immunosuppressive therapy. We analyzed the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score [BVAS]) and relapse as well as the variations over time in
Ключевые слова:
angiotensin receptor antagonist; azathioprine; C reactive protein; cyclophosphamide; dipeptidyl carboxypeptidase inhibitor; glucocorticoid; immunosuppressive agent; mycophenolate mofetil; neutrophil cytoplasmic antibody; prednisone; rituximab; C reactive protein; glucocorticoid; immunoglobulin A; immunologic factor; prednisone; rituximab; abdominal pain; add on therapy; adult; adult onset immunoglobulin A vasculitis; adult onset immunoglobulin A vasculitis; anaphylactoid purpura; Article; Birmingham Vasculitis Activity Score; clinical article; disease activity; disease duration; drug efficacy; drug infusion; drug safety; drug tolerability; estimated glomerular filtration rate; female; follow up; gastrointestinal hemorrhage; gastrointestinal tract; glomerulonephritis; human; human tissue; humoral immune deficiency; immunoglobulin A deficiency; immunoglobulin A nephropathy; immunohistochemistry; immunosuppressive treatment; joint; kidney; kidney biopsy; liver cirrhosis; lower limb; male
Язык текста: Английский
ISSN: 2326-5205
Maritati F.
Fenoglio R.
Pillebout E.
Emmi G.
Urban M. L.
Rocco R.
Nicastro M.
Incerti M.
Goldoni M.
Trivioli G.
Silvestri E.
Mohammad A. J.
Jayne D.
Eriksson P.
Segelmark M.
Novikov P. I. Pavel Igorevich 1982-
Harris H.
Roccatello D.
Vaglio A.
Маритати Ф.
Феноглио Р.
Пиллебоут Е.
Емми Г.
Урбан М. Л.
Роccо Р.
Ниcастро М.
Инcерти М.
Голдони М.
Тривиоли Г.
Силвестри Е.
Мохаммад А. Й.
Йайне Д.
Ерикссон П.
Сегелмарк М.
Новиков П. И. Павел Игоревич 1982-
Харрис Х.
Роccателло Д.
Ваглио А.
Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein)
Текст визуальный непосредственный
Arthritis and Rheumatology
John Wiley & Sons
Vol.70, Issue1 P. 109-114
2018
Статья
angiotensin receptor antagonist azathioprine C reactive protein cyclophosphamide dipeptidyl carboxypeptidase inhibitor glucocorticoid immunosuppressive agent mycophenolate mofetil neutrophil cytoplasmic antibody prednisone rituximab C reactive protein glucocorticoid immunoglobulin A immunologic factor prednisone rituximab abdominal pain add on therapy adult adult onset immunoglobulin A vasculitis adult onset immunoglobulin A vasculitis anaphylactoid purpura Article Birmingham Vasculitis Activity Score clinical article disease activity disease duration drug efficacy drug infusion drug safety drug tolerability estimated glomerular filtration rate female follow up gastrointestinal hemorrhage gastrointestinal tract glomerulonephritis human human tissue humoral immune deficiency immunoglobulin A deficiency immunoglobulin A nephropathy immunohistochemistry immunosuppressive treatment joint kidney kidney biopsy liver cirrhosis lower limb male
Objective: Adult-onset IgA vasculitis (Henoch-Schönlein) (IgAV) is a rare systemic vasculitis characterized by IgA1-dominant deposits. The treatment of adult-onset IgAV is controversial and is based on the combination of glucocorticoids and immunosuppressive agents, but many patients have refractory or relapsing disease despite treatment. Rituximab (RTX) is a B cell–depleting antibody of proven efficacy in antineutrophil cytoplasmic antibody–associated vasculitis. We undertook this study to test the efficacy and safety of RTX in a multicenter cohort of patients with adult-onset IgAV. Methods: In this multicenter observational study, we included patients with adult-onset IgAV who had received RTX either for refractory/relapsing disease or because they had contraindications to conventional glucocorticoid/immunosuppressive therapy. We analyzed the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score [BVAS]) and relapse as well as the variations over time in